<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Selinexor receives Conditional Marketing Authorisation in Europe for the treatment of relapsed and or refractory myeloma patients	</title>
	<atom:link href="https://www.mpeurope.org/selinexor-receives-conditional-marketing-authorisation-in-europe-for-the-treatment-of-relapsed-and-or-refractory-myeloma-patients/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.mpeurope.org/selinexor-receives-conditional-marketing-authorisation-in-europe-for-the-treatment-of-relapsed-and-or-refractory-myeloma-patients/</link>
	<description></description>
	<lastBuildDate>Tue, 30 Mar 2021 08:55:05 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>
</channel>
</rss>
